Nano-hydroxyapatite/β-tricalcium phosphate ceramics scaffolds loaded with cationic liposomal ceftazidime: Preparation, release characteristics in vitro and inhibition to Staphylococcus aureus biofilms

Drug Development and Industrial Pharmacy

Volumn 38, Issue 11, 2012, Pages 1298-1304

  Zhou, Tian Hua ^a,b   Su, Min ^b   Shang, Bei Cheng ^a   Ma, Tao ^a,b   Xu, Gui Li ^a   Li, Hong Liang ^a   Chen, Qing Hua ^c   Sun, Wei ^b   Xu, Yong Qing ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bone regeneration; Controlled drug release; HA TCP ceramic scaffold; Liposomal ceftazidime; Staphylococcus aureus biofilm

Indexed keywords

CALCIUM PHOSPHATE CERAMIC; CEFTAZIDIME; HYDROXYAPATITE; LIPOSOME;

ARTICLE; BIOFILM; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; ELECTRON MICROSCOPY; EVAPORATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARTICLE SIZE; PH; STAPHYLOCOCCUS AUREUS; ZETA POTENTIAL;

ANTI-BACTERIAL AGENTS; BIOCOMPATIBLE MATERIALS; BIOFILMS; BONE SUBSTITUTES; CATIONS; CEFTAZIDIME; CERAMICS; DRUG CARRIERS; DRUG COMPOUNDING; HYDROXYAPATITES; LIPOSOMES; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; NANOSTRUCTURES; POROSITY; SOLUBILITY; STAPHYLOCOCCUS AUREUS; SURFACE PROPERTIES;

EID: 84866933964     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.648196     Document Type: Article

References (27)

1. Jorge LS, Chueire AG, Rossit AR. (2010). Osteomyelitis: a current challenge. Braz J Infect Dis, 14:310-315.
2. Soundrapandian C, Basu D, Sa B, Datta S. (2011). Local drug delivery system for the treatment of osteomyelitis: In vitro evaluation. Drug Dev Ind Pharm, 37:538-546.
3. Lewis K. (2007). Persister cells, dormancy and infectious disease. Nat Rev Microbiol, 5:48-56.
4. Fux CA, Costerton JW, Stewart PS, Stoodley P. (2005). Survival strategies of infectious bioflms. Trends Microbiol, 13:34-40.
5. Advisory Committee on Genetic Modifcation: Annual Report. London; 1999
6. Sutherland IW. (2001). Te bioflm matrix-an immobilized but dynamic microbial environment. Trends Microbiol, 9: 222-227.
7. Anderl JN, Franklin MJ, Stewart PS. (2000). Role of antibiotic penetration limitation in Klebsiella pneumoniae bioflm resistance to ampicillin and ciprofoxacin. Antimicrob Agents Chemother, 44:1818-1824.
8. DiTizio V, Ferguson GW, Mittelman MW, Khoury AE, Bruce AW, DiCosmo F. (1998). A liposomal hydrogel for the prevention of bacterial adhesion to catheters. Biomaterials, 19:1877-1884.
9. Kim JH, Gias M, Jones MN. (1999). Te adsorption of cationic liposomes to Staphylococcus aureus bioflms. Colloid Surface A, 149:561-570.
10. Robinson AM, Bannister M, Creeth JE, Jones MN. (1997). Te interaction of phospholipid liposomes with bacteria and their use in the delivery of bactericides. J Drug Target, 5:25-34.
11. Kadry AA, Al-Suwayeh SA, Abd-Allah AR, Bayomi MA. (2004). Treatment of experimental osteomyelitis by liposomal antibiotics. J Antimicrob Chemother, 54:1103-1108.
12. Ahmed K, Muiruri PW, Jones GH, Scott MJ, Jones MN. (2001). The efect of grafted poly(ethylene glycol) on the electrophoretic properties of phospholipid liposomes and their adsorption to bacterial bioflms. Colloid Surface A, 194:287-296.
13. Pasquardini L, Lunelli L, Vanzetti L, Anderle M, Pederzolli C. (2008). Immobilization of cationic rifampicin-loaded liposomes on polystyrene for drug-delivery applications. Colloids Surf B Biointerfaces, 62:265-272.
14. Sapra P, Allen TM. (2003). Ligand-targeted liposomal anticancer drugs. Prog Lipid Res, 42:439-462.
15. Tamilvanan S, Venkateshan N, Ludwig A. (2008). The potential of lipid-and polymer-based drug delivery carriers for eradicating bioflm consortia on device-related nosocomial infections. J Control Release, 128:2-22.
16. Shuford JA, Steckelberg JM. (2003). Role of oral antimicrobial therapy in the management of osteomyelitis. Curr Opin Infect Dis, 16:515-519.
17. Walenkamp GH, Kleijn LL, de Leeuw M. (1998). Osteomyelitis treated with gentamicin-PMMA beads: 100 patients followed for 1-12 years. Acta Orthop Scand, 69:518-522.
18. Chang W, Colangeli M, Colangeli S, Di Bella C, Gozzi E, Donati D. (2007). Adult osteomyelitis: debridement versus debridement plus Osteoset T pellets. Acta Orthop Belg, 73:238-243.
19. Al-Khazraji KK, Hanna WA, Ahmed PS. (2010). Efect of sintering temperature on some physical and mechanical properties of fabricated hydroxyapatite used for hard tissue healing. Eng Technol J, 28:1880-1892
20. Schoen FJ, Hoerstrup SP, Vacanti JP, Lysaght MJ, Rein D, Mikos AG et al. (2004). Tissue engineering: Biomaterials science. In: Ratner BD, Hofman AS, Schoen FJ, Lemons JE. San Diego, USA: Elsevier Academic Press, 709-750.
21. Weinand C, Pomerantseva I, Neville CM, Gupta R, Weinberg E, Madisch I et al. (2006). Hydrogel-β-TCP scafolds and stem cells for tissue engineering bone. Bone, 38:555-563.
22. Kokubo T, Takadama H. (2006). How useful is SBF in predicting in vivo bone bioactivity? Biomaterials, 27:2907-2915.
23. Taylor G, Kellaway IW, Steven J. (1990). Drug entrapment and release from multilamellar and reverse phase evaporation liposomes. Int J Pharm, 58:49-55.
24. Fry DW, White JC, Goldman ID. (1978). Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem, 90:809-815.
25. Kim JH, Gias M, Jones MN. (1999). The adsorption of cationic liposomes to Staphylococcus aureus bioflms. Colloid Surface A, 149:561-570.
26. Frutos G, Pastor JY, Martínez N, Virto MR, Torrado S. (2009). Infuence of lactose addition to gentamicin-loaded acrylic bone cement on the kinetics of release of the antibiotic and the cement properties. Acta Biomater, 6:804-811.
27. Frutos P, Diez-Peña E, Frutos G, Barrales-Rienda JM. (2002). Release of gentamicin sulphate from a modifed commercial bone cement. Efect of (2-hydroxyethyl methacrylate) comonomer and poly(N-vinyl-2-pyrrolidone) additive on release mechanism and kinetics. Biomaterials, 23:3787-3797.